TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro Inhalation Capsules were developed by Novartis under the name of QVA149 and will be available to the 5.3 million Japanese patients who may be living with COPD4. The approval triggers a $2.5m milestone payment to Sosei.
Help employers find you! Check out all the jobs and post your resume.
